Therefore, the anti-PD-L1 targeting to the PD-L1 on tumor cells may be more easily resisted in comparison with anti-PD-1 targeting to the PD-1 on immune cells, which needs to be explored in future studies. Here, PDCD1 is linked to neoplasm.